Literature DB >> 15084552

Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil.

C-J A Lindholm1, O Fredholm, S-J Möller, N Edvardsson, T Kronvall, T Pettersson, V Firsovaite, A Roijer, C J Meurling, P G Platonov, S B Olsson.   

Abstract

OBJECTIVE: To evaluate prospectively the effects of pretreatment with verapamil on the maintenance of sinus rhythm after direct current (DC) cardioversion.
DESIGN: Randomised, active control, open label, parallel group comparison of verapamil versus digoxin. SETTINGS: Multicentre study in three teaching and three non-teaching hospitals in Sweden. PATIENTS: 100 consecutive patients with atrial fibrillation (AF) of at least four weeks' duration and indications for cardioversion were assigned randomly to two groups, one treated with verapamil (verapamil group) and the other with digoxin (digoxin group) before cardioversion. Fifty patients were assigned randomly to each treatment arm. After dropout of four patients from the digoxin group and seven patients from the verapamil group, data obtained from 89 patients were analysed.
INTERVENTIONS: After randomly assigned pretreatment with either verapamil or digoxin for four weeks, DC cardioversion was performed. If sinus rhythm was restored then verapamil treatment was discontinued. MAIN OUTCOME MEASURES: The rate of AF recurrence was assessed one, four, eight, and 12 weeks after cardioversion.
RESULTS: 6 patients in the verapamil treated group and none in the digoxin treated group reverted to sinus rhythm spontaneously (p < 0.05). DC cardioversion restored sinus rhythm in 24 of 37 (65%) patients in the verapamil group and 41 of 46 patients (89%) in the digoxin group (p < 0.05). After 12 weeks' follow up 28% (13 of 46) of digoxin pretreated patients versus 9% (four of 43) of verapamil pretreated patients remained in sinus rhythm (p < 0.05).
CONCLUSION: Pretreatment with verapamil alone does not improve maintenance of sinus rhythm after DC cardioversion in patients with AF. The rate of spontaneous cardioversion may be improved by verapamil.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084552      PMCID: PMC1768216          DOI: 10.1136/hrt.2003.017707

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  35 in total

1.  Effect of verapamil on secondary cardioversion in patients with early atrial fibrillation recurrence after electrical cardioversion.

Authors:  Antonio De Simone; Pietro Turco; Carmine De Matteis; Vincenzo La Rocca; Pasquale Nocerino; Luciano Greco; Costantino Astarita; Vincenzo Messina; Raffaele Rotunno; Gianfranco Iaconelli; Eugenio Stabile; Giuseppe Stabile
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

2.  Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling.

Authors:  S H Lee; W C Yu; J J Cheng; C R Hung; Y A Ding; M S Chang; S A Chen
Journal:  Circulation       Date:  2000-01-18       Impact factor: 29.690

3.  Induction of delayed repolarization during chronic beta-receptor blockade.

Authors:  N Edvardsson; S B Olsson
Journal:  Eur Heart J       Date:  1985-11       Impact factor: 29.983

4.  Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias.

Authors:  R L Rinkenberger; E N Prystowsky; J J Heger; P J Troup; W M Jackman; D P Zipes
Journal:  Circulation       Date:  1980-11       Impact factor: 29.690

5.  Can short-term verapamil therapy reduce the recurrence of atrial fibrillation after successful low energy intracardiac cardioversion?

Authors:  F Zardo; F Antonini-Canterin; M Brieda; E Hrovatin; D Pavan; C Burelli; E Cervesato; G L Nicolosi
Journal:  Ital Heart J       Date:  2001-07

Review 6.  Atrial fibrillation--a review of course and prognosis.

Authors:  P Petersen; J Godtfredsen
Journal:  Acta Med Scand       Date:  1984

7.  Epidemiologic features of chronic atrial fibrillation: the Framingham study.

Authors:  W B Kannel; R D Abbott; D D Savage; P M McNamara
Journal:  N Engl J Med       Date:  1982-04-29       Impact factor: 91.245

8.  Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation.

Authors:  M Shenasa; T Kus; M Fromer; R A LeBlanc; M Dubuc; R Nadeau
Journal:  Am J Cardiol       Date:  1988-09-01       Impact factor: 2.778

Review 9.  How to enhance acute outcome of electrical cardioversion by drug therapy: importance of immediate reinitiation of atrial fibrillation.

Authors:  Trudeke Van Noord; Isabelle C Van Gelder; Harry J G M Crijns
Journal:  J Cardiovasc Electrophysiol       Date:  2002-08

10.  [Electrophysiological effect of verapamil on human atrium].

Authors:  M Inoue; D Inoue; I Omori; T Shirayama; Y Yamahara; J Asayama; H Katsume; M Nakagawa
Journal:  Kokyu To Junkan       Date:  1991-09
View more
  2 in total

Review 1.  Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.

Authors:  Naqash J Sethi; Emil E Nielsen; Sanam Safi; Joshua Feinberg; Christian Gluud; Janus C Jakobsen
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

2.  Which antiarrhythmic drug to choose after electrical cardioversion: A study on non-valvular atrial fibrillation patients.

Authors:  Hye Bin Gwag; Kwang Jin Chun; Jin Kyung Hwang; Seung-Jung Park; June Soo Kim; Kyoung-Min Park; Young Keun On
Journal:  PLoS One       Date:  2018-05-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.